Interstitial pneumonia disease induced by osimertinib combined with savolitinib targeted therapy in a lung cancer patient: A case report.

Rationale: MET-TKI is a late-stage treatment for drug-resistant NSCLC that has been marketed in recent years, and interstitial lung disease may be a rare adverse reaction. This case reports the development of interstitial lung disease in a patient with advanced lung cancer who developed during treatment with savolitinib after resistance to osimertinib.

Patient Concerns: A 74-year-old female diagnosed with lung adenocarcinoma was referred to our hospital with chest tightness and shortness of breath following treatment with osimertinib plus savolitinib.

Diagnose: Chest CT of the patient shows interstitial changes in both lungs, and drug-related interstitial lung disease is considered in the context of the patient previous condition.

Interventions: The patient is treated with methods such as glucocorticoids, anti-infection, and mechanical ventilation.

Outcomes: At the 1-year follow-up visit, the patient condition of interstitial lung disease was relatively stable. The patient has passed away due to tumor progression.

Lessons: This case reported interstitial lung disease following osimertinib plus savolitinib. This suggests that healthcare providers should be aware of early symptoms of interstitial lung disease during treatment and treat them appropriately to prevent symptoms from worsening.